This Azer-cel phase 1b trial will recruit quickly for one...

First 5 Last

Share
Profile

Follow
Wedgeman7

2,012 Posts.

615

08/09/24

10:40

Post #: 75579325
Share

Originally posted by Ragnarolf: ↑

Well what an interesting week of share price action. For novice investors out there don't dismay. I think this is a A typical example of buy the rumour sell the fact. And has no real bearing on the quality of the data that the company released.

As I previously posted Azercel phase 1b is looking stellar, and could very well go the full distance.
4 patients in. 3 assessed. 2 complete responses and 1 pseudo progression, which has the potential to be upgraded. If so we could be looking at a 100% overall response rate 66% complete response rate.

I believe on the webinar they've mentioned they've now dosed patient 5. Unlike the oncarlytic viruses we are used to with imugene taking seemingly forever to enrol patients and report back data. T cells therapy (Azercel) is very fast acting, with peak action hitting at day 10, and first scan at day 28.

In 28 days the company will have 2 more patients available to assess increasing their data set from 3 to 5. Looking at the above webinar pack it does appear to be managements intent to provide further phase 1b trail update/s in 2024.

3 patients data just isn't going to gain much traction and interest from the stock market and big pharma. But I now have confidence IMU are onto a winning ticket with Azercel. with 15 trial sites they have the ability to enrol patients very quickly, and if we see more complete responses on the next patients in. I am expecting more and fast coming updates from management.

Management need a capital raise of $60M - $80M within the next 6 months to keep this rolling (will see Azercel through to phase 3). Therefore they need to build interest with investors and fast. More Azercel 1b data is their best lever to pull.

3 patients it's really hard to pull any meaningful trend. But we could be sitting on a treatment with a 70% complete response rate in very unwell and sick people who have failed 3-4 previous lines of therapy (including currently approved T cells therapy).

Don't dismay, I feel it's finally time to start getting excited. Get your cash ready for the capital raise. Don't bet your house! Only play with what you can afford to lose. This stock remains extremely high risk return.

In my opinion, not advice. Please do your own research

Expand

This Azer-cel phase 1b trial will recruit quickly for one specific reason:
this trial is the last chance saloon for patients who have failed 4+ prior treatments including autogolous CAR T which also means they have possibly spent a small fortune and are unlikely to fund further treatments. A free trial showing complete responses is very attractive.

IMU Price at posting: 5.4¢ Sentiment: None Disclosure: Held
41 Upvote

1 Great analysis

Reply

Top Stories

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

IMA

Issues emerging as Australian companies tackle critical minerals challenge

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

First 5 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	204609	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	162906	4

View Market Depth

No.	Vol.	Price($)
1	2800	0.050
4	765205	0.049
36	4313184	0.048
46	4981732	0.047
42	3489042	0.046

Price($)	Vol.	No.
0.048	607468	7
0.049	3422777	10
0.050	4543810	24
0.051	4434080	10
0.052	2536519	9

Last trade - 09.42am 11/10/2024 (20 minute delay)

IMU (ASX) Chart

Day chart unavailable

This Azer-cel phase 1b trial will recruit quickly for one...

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Issues emerging as Australian companies tackle critical minerals challenge

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

This Azer-cel phase 1b trial will recruit quickly for one...

Top Stories

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Issues emerging as Australian companies tackle critical minerals challenge

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News